Waverley Pharma Competitors and Similar CompaniesClear all
Waverley Pharma's competitors and similar companies include Puma Biotechnology, Progenics Pharmaceuticals, Biocon and RS Research.
 Waverley Pharma Waverley Pharma is a specialty pharma company developing and commercializing therapeutics that aim to cure generic oncology. |  Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. |  Progenics Pharmaceuticals Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients. |  RS Research RS Research is a pharmaceutical company developing nanomedicines based on innovative drug delivery platforms for targeted cancer therapy. | ||
Founding Date | Founding Date 2014 | Founding Date 2010 | Founding Date 1986 | Founding Date 1978 | Founding Date 2015 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Private |
Tags | |||||
Locations | Locations Winnipeg, CA HQ | Locations Los Angeles, US HQ | Locations New York, US HQ Billerica, US | Locations Bengaluru, IN HQ Bengaluru, IN Nanakramguda, IN Dublin, IE Kuala Lumpur, MY Puchong, MY Delémont, CH see more | Locations Epalinges, CH HQ |
Employees | Employees N/A | Employees 27214% decrease | Employees 49 | Employees 16,5612% increase | Employees 254% decrease |
Valuation ($) | Valuation ($) 582.4 k | Valuation ($) 136.8 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.3m (FY, 2025) | Revenue (est.) $228.4m (FY, 2025) | Revenue (est.) $35m (FY, 2019) | Revenue (est.) ₹167.8b (FY, 2026) | Revenue (est.) N/A |
Cost of goods | Cost of goods $752k (FY, 2025) | Cost of goods $58.2m (FY, 2025) | Cost of goods $3.2m (FY, 2019) | Cost of goods ₹56.9b (FY, 2026) | Cost of goods N/A |
Gross profit | Gross profit $597k (FY, 2025) | Gross profit $170.2m (FY, 2025) | Gross profit $31.8m (FY, 2019) | Gross profit ₹115.8b (FY, 2026) | Gross profit N/A |
Net income | Net income ($499k) (FY, 2025) | Net income N/A | Net income ($68.6m) (FY, 2019) | Net income ₹3.7b (FY, 2026) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
Puma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View companyProgenics Pharmaceuticals
HQ
New York, US
Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients.
View company
Biocon
HQ
Bengaluru, IN
Employees
16,561↑ 2% increase
Biocon is a company that develops and manufactures biopharmaceutical products.
View companyRS Research
HQ
Epalinges, CH
Employees
25↓ 4% decrease
RS Research is a pharmaceutical company developing nanomedicines based on innovative drug delivery platforms for targeted cancer therapy.
View company